menu

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

FDA D.I.S.C.O.: Avelumab in Merkel Cell Carcinoma

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to access this content.
Completing the pre-survey is required to view this content.
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

Recommended
Details
Comments
  • Overview

    FDA medical oncologists discuss the agency’s March 23, 2017 approval of avelumab for the treatment of patients 12 years and older with metastatic Merkel cell carcinoma.

    Released May 22, 2017

Facebook Comments

Schedule29 Mar 2024